Blockchain Registration Transaction Record

GeoVax Completes Key Milestones for Pivotal Phase 3 GEO-MVA Study

GeoVax announces completion of manufacturing, regulatory, and preclinical milestones for GEO-MVA, positioning the mpox/smallpox vaccine for a pivotal Phase 3 study in Q4 2026.

This news matters because it signifies progress in addressing the global need for mpox and smallpox vaccines. GeoVax's GEO-MVA program aims to expand manufacturing capacity and provide an additional reliable source of MVA vaccine for government preparedness programs. Successful completion of the Phase 3 study could lead to regulatory approval and commercialization, enhancing biosecurity and public health response capabilities against orthopoxvirus outbreaks.